Alumis Inc. (ALMS) stock
ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.14−0.46 (-8.21%)
Close on Nov 16, 2026Market cap $665.30MP/E –Yield –
Alumis r&d expenses
Research and development expenses are spending on new products and technology.
Alumis's R&D Expenses for the twelve months ending Jun 30, 2026 was $347.50M, down 8.7% year over year. For fiscal 2025 it was $386.00M, up 45.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $386.00M | +45.4% |
| FY2024 | Dec 31, 2024 | $265.55M | +92.9% |
| FY2023 | Dec 31, 2023 | $137.68M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $85.34M | -21.5% |
| Q1 FY2026 | Mar 31, 2026 | $81.54M | -15.6% |
| Q4 FY2025 | Dec 31, 2025 | $82.79M | -5.1% |
| Q3 FY2025 | Sep 30, 2025 | $97.84M | +11.4% |
| Q2 FY2025 | Jun 30, 2025 | $108.76M | +123.9% |
| Q1 FY2025 | Mar 31, 2025 | $96.62M | +130.3% |
| Q4 FY2024 | Dec 31, 2024 | $87.20M | +152.0% |
| Q3 FY2024 | Sep 30, 2024 | $87.82M | +132.4% |
| Q2 FY2024 | Jun 30, 2024 | $48.57M | +47.8% |
| Q1 FY2024 | Mar 31, 2024 | $41.96M | – |
| Q4 FY2023 | Dec 31, 2023 | $34.61M | – |
| Q3 FY2023 | Sep 30, 2023 | $37.79M | – |
| Q2 FY2023 | Jun 30, 2023 | $32.85M | – |
See a number that looks wrong?